RCS - Frontier IP Group - Syva signs option to license agreement with TVG

Frontier IPAnnouncement

16/04/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250416:nRSP1617Fa&default-theme=true

RNS Number : 1617F  Frontier IP Group plc  16 April 2025

REACH - a non-regulatory announcement

AIM: FIPP

16 April 2025

 

Frontier IP Group plc

("Frontier IP" or the "Group")

 

 

Portfolio news - Global animal health group Syva signs option to license
agreement with The Vaccine Group

 

Frontier IP, a specialist in commercialising intellectual property, today
notes the following announcement from portfolio company The Vaccine Group
("TVG" or the "Company") that it has entered a collaboration with leading
Spanish animal health group Syva to develop a vaccine against Streptococcus
suis ("S.suis").

 

Syva is a global producer and supplier of animal health products, operating in
nearly 70 countries. It will have an option to negotiate an exclusive
worldwide licence  for any vaccine developed through the collaboration.

 

The work will build on work already undertaken by TVG, a University of
Plymouth spin out. This has been supported by two Innovate UK grants,
including a £1 million award financed by the UK Department for Environment,
Food and Rural Affairs for a project led by TVG and including the University
of Cambridge and the University of Plymouth. Frontier IP holds a 16.7 per cent
equity stake in the Company.

 

S. suis is a widespread, harmful and zoonotic pig disease that causes severe
economic harm to pig producers worldwide. The disease is endemic in the global
pig population, estimated at 780 million strong, and affects up to 60 per cent
of pig farms in European countries. It can jump from pigs to humans causing
meningitis, septicaemia and other symptoms.

 

Control of S.suis is largely through antibiotics, raising the risk of
resistant strains of the disease developing. However, there is no current
vaccine which is fully effective against the disease because it comes in many
different strains, a problem which TVG's vaccines are being designed to
address.

 

 

Frontier IP Chief Executive Officer Neil Crabb said: "Streptococcus suis can
be a highly damaging disease, not just to pig farmers' livelihoods, but also
to human health. The Syva collaboration is yet more good news from TVG. It is
a  further testament to the strength of the Company's flexible and novel
vaccine technology. This is now underpinning the development of vaccines
targeting 12 different livestock and companion animal diseases. I am also
excited by the potential for use in companion animal therapeutics."

 

 

The Vaccine Group statement begins:

 

 

             TVG and Syva sign option to license agreement for
important pig vaccine

 

TVG is delighted to announce that it has started a collaboration with the
Spanish animal health company Syva for the development of a vaccine against
Streptococcus suis (S.suis).

 

The programme builds upon work previously conducted by TVG with the support of
Innovate UK under two separate grants. S.suis  is a global pathogen with a
significant impact on health and productivity in commercial swine units and is
a potential source of a serious zoonotic disease.

 

Control of the disease is one of the major drivers of antibiotic use in
commercial swine production. There is a global initiative to reduce the volume
of antibiotic use as a means of addressing the development and onward
transmission of Anti-Microbial Resistance (AMR).

 

Currently available commercial S.suis vaccines are not fully effective due to
frequent strain variation and the presence of multiple serotypes around the
world. This has driven an upsurge in the use of un-licensed autogenous
vaccines, which are expensive and, as killed whole bacterin vaccines, have
limited efficacy.

 

TVG's vaccine candidate is designed to offer protection against a wide range
of strains and serotypes of S.suis through the targeted selection of
multi-serotype antigens that are preserved across multiple strains. Through
participation in this collaboration Syva will obtain the right to acquire an
exclusive licence to the vaccine globally.

 

Since its founding in 1941, Syva has been committed to researching
opportunities and pursuing scientific development to innovate and deliver
efficient solutions for the animal health sector. SYVA is present in nearly 70
countries around the world, through its four subsidiaries located in Portugal,
Mexico, and Turkey, and most recently, in 2023, in the Philippines, as well as
through an extensive network of local distributors.

 

Syva is headquartered in León, Spain's third largest pharmaceutical hub after
Madrid and Barcelona. It has three production plants, one dedicated
specifically to vaccine production and another to beta-lactam production.

 

Thanks to regular investments over the years, Syva boasts state-of-the-art
facilities and ensures that all stages of the development and production of
its veterinary medicines follow best practices. Syva seeks to embrace its
commitment to society, and all its efforts are always driven by the desire to
protect the human-animal-environment ecosystem, in accordance with the
essential principles of One Health.

 

To this end, among other things, it supports the principles of responsible
antibiotic use and continuously ensures that its activities are in line with
sustainable development and compliance with environmental protection
standards, making appropriate strategic decisions and investments.

 

 

Find out more about TVG and our core platform technology
at www.thevaccinegroup.com
(https://eur02.safelinks.protection.outlook.com/?url=http%3A%2F%2Fwww.thevaccinegroup.com%2F&data=05%7C02%7C%7Cf9e55349451b4046769e08dd781f9cc1%7Cbffa551e16cb466f8c6a2519187fe364%7C0%7C0%7C638798799377980348%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=MPhi6YjfmumsOl8dsFtpGdkQX3O7GV1ozGP5BSz6rOI%3D&reserved=0)

 

Find out more about Syva at https://Syva.es/
(https://eur02.safelinks.protection.outlook.com/?url=https%3A%2F%2Fsyva.es%2F&data=05%7C02%7C%7Cf9e55349451b4046769e08dd781f9cc1%7Cbffa551e16cb466f8c6a2519187fe364%7C0%7C0%7C638798799378000328%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&sdata=qmPArBESRNr31Adp7SrdCgpWulOJZ4rgW8Dtqw8sbjs%3D&reserved=0)

.

 

 

The Vaccine Group Statement ends

 

 

ENQUIRIES

            Frontier IP Group Plc                                                   T: 020 7332 2338
            Neil Crabb, Chief Executive                                             neil@frontierip.co.uk

            Andrew Johnson, Communications and investor relations                   M: 07464 546 025

            andrew.johnson@frontierip.co.uk

            Company website: www.frontierip.co.uk (http://www.frontierip.co.uk/)
            Allenby Capital Limited (Nominated Adviser)                             T: 0203 328 5656
            Nick Athanas / Dan Dearden-Williams

 The Vaccine Group                                                                  Jeremy.salt@thevaccinegroup.co.uk
 Jeremy Salt, CEO

 

 

ABOUT FRONTIER IP

Frontier IP unites science, finance and industry by identifying strong
intellectual property and accelerating its development through a range of
commercialisation services. A critical part of the Group's work is involving
relevant industry partners at an early stage of development to ensure
technology meets real world demands and needs.

The Group looks to build and grow a portfolio of equity stakes and licence
income by taking an active involvement in spin-out companies, including
support for fund raising and collaboration with relevant industry partners at
an early stage of development.

About Reach announcements

This is a RNS Reach announcement. Reach is an investor communication service
aimed at assisting listed and unlisted (including AIM quoted) companies
to distribute media only / non-regulatory news releases into the public
domain. Information required to be notified under the AIM Rules for
Companies, Market Abuse Regulation or other regulation would be disseminated
as an RNS regulatory announcement and not on Reach.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAFLFSESRIELIE